Meiragtx Holdings ( (MGTX) ) has released its Q4 earnings. Here is a breakdown of the information Meiragtx Holdings presented to its investors.
MeiraGTx Holdings plc is a clinical-stage genetic medicines company focused on developing innovative therapies for inherited and common diseases, leveraging its proprietary technology and extensive in-house manufacturing capabilities. In its recent earnings report, MeiraGTx announced a strategic collaboration with Hologen AI, which includes a $200 million upfront payment and the formation of a joint venture to advance the development of AAV-GAD for Parkinson’s disease. The company also reported positive clinical data for its AAV-GAD program and received FDA designations for its AAV2-hAQP1 treatment for radiation-induced xerostomia and rAAV8.hRKp.AIPL1 for LCA4, among other achievements. Financially, MeiraGTx reported a net loss of $147.8 million for 2024, with increased expenses in research and development and general administration. Looking forward, MeiraGTx aims to continue its innovative work in genetic medicine, addressing unmet medical needs and creating shareholder value, supported by its robust pipeline and strategic partnerships.